Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes

European Journal of Endocrinology

Volumn 164, Issue 3, 2011, Pages 371-379

  Engelen, Lian ^a,b   Lund, Søren S ^c   Ferreira, Isabel ^a,b   Tarnow, Lise ^c   Parving, Hans Henrik ^d,e   Gram, Jørgen ^f,g   Winther, Kaj ^h   Pedersen, Oluf ^e,i,j   Teerlink, Tom ^k   Barto, Rob ^k   Stehouwer, Coen D A ^a,b   Vaag, Allan A ^c,l   Schalkwijk, Casper G ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STENO DIABETES CENTER   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g Frederiksberg Hospital ^*  (Denmark)

^h FREDERIKSBERG HOSPITAL   (Denmark)

ⁱ HAGEDORN RESEARCH INSTITUTE   (Denmark)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l LUND UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 DEOXYGLUCOSONE; ALBUMIN; ALPHA DICARBONYL 3 DEOXYGLUCOSONE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; REPAGLINIDE; UNCLASSIFIED DRUG; 3-DEOXYGLUCOSONE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; DEOXYGLUCOSE; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; ADVANCED GLYCATION END PRODUCT;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; GLYCEMIC CONTROL; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEMOGLOBIN BLOOD LEVEL; INFLAMMATION; PROTEIN BLOOD LEVEL;

CARBAMATES; CONFIDENCE INTERVALS; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PIPERIDINES;

EID: 79951971683     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0851     Document Type: Article

References (32)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 813-820. (doi:10.1038/414813a)
2. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008 196 9-21. (doi:10.1016/j.atherosclerosis.2007.07.025)
3. Yamagishi S, Nakamura K, Matsui T, Ueda S, Noda Y & Imaizumi T. Inhibitors of advanced glycation endproducts (AGEs): potential utility for the treatment of cardiovascular disease. Cardiovascular Therapeutics 2008 26 50-58. (doi:10.1111/j.1527-3466.2007.00038.x)
4. Thornalley PJ, Langborg A & Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochemical Journal 1999 344 109-116. (doi:10.1042/0264-6021:3440109)
5. Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, Suzuki K, Miyazaki H, Yamashita Y, Inaba K & Kasuga M. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 2003 26 1889-1894. (doi:10.2337/diacare.26.6.1889)
6. Schindhelm RK, Alssema M, Scheffer PG, Diamant M, Dekker JM, Barto R, Nijpels G, Kostense PJ, Heine RJ, Schalkwijk CG & Teerlink T. Fasting and postprandial glycoxidative and lipoxidative stress are increased in women with type 2 diabetes. Diabetes Care 2007 30 1789-1794. (doi:10.2337/dc06-2585)
7. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS & Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005 54 3274-3281. (doi:10.2337/diabetes.54.11.3274)
8. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Archives of Biochemistry and Biophysics 2003 419 31-40. (doi:10.1016/j.abb.2003.08.013)
9. Beisswenger PJ, Howell SK, Touchette AD, Lal S & Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999 48 198-202. (doi:10.2337/diabetes.48.1.198)
10. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M & Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation endproduct formation. Biochemical Pharmacology 1999 58 1765-1773. (doi:10.1016/S0006-2952(99)00263-4)
11. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A & Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010 59 1038-1045. (doi:10.2337/db09-1455)
12. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 854-865. (doi:10.1016/S0140-6736(98)07037-8)
13. Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag AA. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European Journal of Endocrinology 2008 158 35-46. (doi:10.1530/EJE-07-0500)
14. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag A. Targeting hyperglycaemia with either metformin or repaglinide in nonobese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism 2007 9 394-407. (doi:10.1111/j.1463-1326.2007.00713.x)
15. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, Winther K, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag AA. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. European Journal of Endocrinology 2008 158 631-641. (doi:10.1530/EJE-07-0815)
16. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM & Teerlink T. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Peritoneal Dialysis International 1999 19 325-333.
17. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HG, Schlingemann RO, Tarnow L, Parving HH, Stehouwer CD & van Hinsbergh VW. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999 48 2446-2453. (doi:10.2337/diabetes.48.12. 2446)
18. ε-(carboxyethyl) lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clinical Chemistry 2004 50 1222-1228. (doi:10.1373/clinchem.2004. 031286)
19. De Jager J, Kooy A, Lehert P, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ & Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of Internal Medicine 2005 257 100-109. (doi:10.1111/j.1365-2796.2004.01420.x)
20. Esposito K, Giugliano D, Nappo F & Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004 110 214-219. (doi:10.1161/01.CIR.0000134501.57864.66)
21. Manzella D, Grella R, Abbatecola AM & Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005 28 366-371. (doi:10.2337/diacare.28.2.366)
22. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD & Szwergold BS. α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001 24 726-732. (doi:10.2337/diacare.24.4.726)
23. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N & Tuomilehto J. Postprandial glucose regulation and diabetic complications. Archives of Internal Medicine 2004 164 2090-2095. (doi:10.1001/archinte.164.19. 2090)
24. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP & Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Journal of the American Medical Association 2006 295 1681-1687. (doi:10.1001/jama.295.14.1681)
25. Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. Journal of Chromatography. B, Biomedical Sciences and Applications 1999 731 23-36. (doi:10.1016/S0378-4347(99)00113-9)
26. ε-(carboxymethyl)lysine and 3-DG-imidazolone are majorAGE structures in protein modification by 3-deoxyglucosone. Journal of Biochemistry 2004 136 351-358. (doi:10.1093/jb/mvh124)
27. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH & Stehouwer CD. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003 26 2165-2173. (doi:10.2337/diacare.26.7.2165)
28. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH & Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia 2005 48 370-378. (doi:10.1007/s00125-004-1628-8)
29. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM & Stehouwer CD. Endothelial dysfunction and lowgrade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 1086-1093. (doi:10.1161/01.ATV.0000215951.36219.a4)
30. Brouwers O, Niessen PM, Haenen G, Miyata T, Brownlee M, Stehouwer CD, De Mey JG & Schalkwijk CG. Hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stress. Diabetologia 2010 53 989-1000. (doi:10.1007/s00125-010-1677-0)
31. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H & Tschoepe D. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation endproducts in individuals with type 2 diabetes. Diabetes Care 2006 29 2064-2071. (doi:10.2337/dc06-0531)
32. Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW & Welborn TA. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. Journal of Internal Medicine 2003 254 555-563. (doi:10.1111/j.1365-2796.2003. 01229.x)